Zulueta M A, Vincent E, Correas I, Villanueva M L, Felíu J E, Marco J
Diabete Metab. 1982 Mar;8(1):47-51.
The human pancreatic polypeptide (hPP) responses to insulin injection (0.05-0.1 U/kg, i.v.) and to endogenous insulin release as provoked by i.v. tolbutamide (1 g) and oral glucose administration (1.75 g/kg) have been examined. The injection of insulin or tolbutamide was followed by a marked elevation of circulating hPP which was abolished by preventing the hypoglycemic effect of these substances by intravenous glucose infusion. Atropine pre-treatment (1 mg, i.v.) also blocked the hPP responses to insulin- or tolbutamide-induced hypoglycemia. Approximately three hours after glucose ingestion, coinciding with the hypoglycemic phase of the test, there was a clear-cut increase in circulating hPP. This hPP response was blunted by impeding the blood sugar fall to sub-baseline values-by means of a glucose infusion-as well as by prior atropinization. It is concluded that: 1) The hPP secretagogue activity of both, insulin and tolbutamide is mediated by their hypoglycemic effect. 2) The elevation of circulating hPP, which occurs during the late hypoglycemic phase of an oral glucose test, is also dependent upon the blood sugar decline to sub-baseline values. 3) Under the above conditions, the hPP response to hypoglycemia can be blocked by atropine, thus indicating that it is due to activation of the cholinergic system and not to the direct effect of glucose lack at the level of the hPP-cell.
已研究了人胰多肽（hPP）对静脉注射胰岛素（0.05 - 0.1 U/kg）、静脉注射甲苯磺丁脲（1 g）和口服葡萄糖（1.75 g/kg）所诱发的内源性胰岛素释放的反应。注射胰岛素或甲苯磺丁脲后，循环中的hPP显著升高，而通过静脉输注葡萄糖防止这些物质的降血糖作用可消除这种升高。阿托品预处理（静脉注射1 mg）也可阻断hPP对胰岛素或甲苯磺丁脲诱导的低血糖的反应。摄入葡萄糖约三小时后，与试验的低血糖期一致，循环中的hPP明显增加。通过葡萄糖输注阻碍血糖降至基线以下值以及预先用阿托品处理，均可减弱这种hPP反应。得出以下结论：1）胰岛素和甲苯磺丁脲的hPP促分泌活性均由其降血糖作用介导。2）口服葡萄糖试验后期低血糖期出现的循环hPP升高也依赖于血糖降至基线以下值。3）在上述条件下，阿托品可阻断hPP对低血糖的反应，因此表明这是由于胆碱能系统的激活，而非hPP细胞水平上葡萄糖缺乏的直接作用。
